Skip to main content
Michael Para, MD, Infectious Disease, Columbus, OH

MichaelParaMD

Infectious Disease Columbus, OH

HIV/AIDS Medicine

Professor

Dr. Para is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Para's full profile

Already have an account?

  • Office

    1581 Dodd Dr
    4th Floor
    Columbus, OH 43210
    Phone+1 614-293-4854
    Fax+1 614-293-8102

Education & Training

  • University of Chicago
    University of ChicagoFellowship, Infectious Disease, 1977 - 1981
  • University of Chicago
    University of ChicagoResidency, Internal Medicine, 1974 - 1977
  • Ohio State University College of Medicine
    Ohio State University College of MedicineClass of 1974

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 1980 - 2026
  • IL State Medical License
    IL State Medical License 1975 - 1982
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

  • College of Medicine Best Teaching and Learning Method 2015
  • Department of Internal Medicine Student teach Award 2015
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials  
    Treasure GC, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Para M, Gandhi RT, Li JZ., J Acquir Immune Defic Syndr, 1/20/2016
  • The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption  
    Li JZ, Etemad B, Ahmed H, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Lederman MM, Para M, Gandhi RT, AIDS, 1/1/2016
  • Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257  
    Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Ke..., Clin Infect Dis, 1/15/2015
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Lectures

  • Computer Assisted Instruction - AIDS: Vignettes for Dental Professionals, Four Case Presentations 
    1/1/1991

Other

  • Understanding HIV Infection 
    Para MF, Audio Digest, Internal Medicine
    1/19/1990

Press Mentions

  • Ohio Prisons Chief Walks Back Claim That 96% of Prison COVID-19 Cases Were Asymptomatic
    Ohio Prisons Chief Walks Back Claim That 96% of Prison COVID-19 Cases Were AsymptomaticJune 18th, 2020
  • HIV/AIDS History and the Normal Heart
    HIV/AIDS History and the Normal HeartMarch 16th, 2017
  • From the Forefront to 40 Years Later, Reflecting on the HIV Crisis
    From the Forefront to 40 Years Later, Reflecting on the HIV CrisisJune 26th, 2021

Grant Support

  • Clinical Trial: Treatment Of Inadequate CD4+ Lymphocyte RecoveryNational Center For Research Resources2008
  • ACTG 5177: An Observational Study Of PharmacokineticsNational Center For Research Resources2005–2006
  • Intensive PK Study Of Lopinavir/Ritonavir And Gw433908National Center For Research Resources2004
  • ACTG A5043: Pharmacokinetic Interaction Studies Of APVNational Center For Research Resources2004
  • Phase II, Randomized, OPEN Label, Comparative Trial Of Salvage AntiretroviralNational Center For Research Resources2000–2001
  • Establishment Of Patient Cohort For Ohio State Univ AIDS Clinical TrialsNational Center For Research Resources1998–2001
  • Delaviridine Mesylate In Combination With Zidovudine &2 Doses LamivudineNational Center For Research Resources1998–2001
  • Establishment Of A Patient Cohort For The AIDS ClinicalNational Center For Research Resources2000
  • Clinical CenterDivision Of Blood Diseases And Resources1995–2000
  • Phase I Randomized Dose/Formulation Comparison Study Of Sc52151National Center For Research Resources1995
  • A Phase 1 Concentrated Multidose Study Of Atevirine MesylateNational Center For Research Resources1995
  • Core--Virology Core LaboratoryNational Institute Of Allergy And Infectious Diseases1992–1995
  • Natural History Of HIV Seropositive CohortsNational Center For Research Resources1988–1995
  • Assess Safety, Tolerance, Pharmacokinetics And Dev. Of Decr. HIV-1 To ATVNational Center For Research Resources1994
  • A Phase 1 Concentration-Targeted Multidose Study Of Atevirdine MesylateNational Center For Research Resources1994
  • Establishment Of A Cohort And Clinical ManagementNational Institute Of Allergy And Infectious Diseases1987–1991
  • AZT In ARC And AIDS Patients--Natural History StudyNational Center For Research Resources1988